Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Summary
- Recent investigations have studied newer agents as part of NRTI-sparing regimens in treatment-naive patients
- The IAS-USA guidelines mention 2 options, pending further data on other strategies, for the rare situation in which a patient cannot receive abacavir, tenofovir AF, or tenofovir DF[IASUSA ART]:
- Darunavir plus ritonavir plus raltegravir, only if baseline CD4+ cell count > 200 cells/mm3 and HIV-1 RNA < 100,000 copies/mL
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Initial Antiretroviral Therapy